FLT3 and leukemia: Based on that, we verified that patient’s cells harboring FLT3 mutations, a frequent secondary event in KMT2A-r leukemia, showed higher sensitivity to Foretinib, suggesting that this drug might turn into a therapeutic option for these subgroups.